Status:
COMPLETED
Irbesartan, Ciprofibrate and Their Combination Onto the Endothelial Functions
Lead Sponsor:
Sanofi
Collaborating Sponsors:
Bristol-Myers Squibb
Conditions:
Hypertension
Dyslipidemia
Eligibility:
All Genders
45-70 years
Phase:
PHASE4
Brief Summary
The rationale of the study is to clarify whether the supplementation of irbesartan with ciprofibrate could increase the antihypertensive effect, could improve the endothelial functions, and/or could a...
Eligibility Criteria
Inclusion
- hypertensive + dyslipidemic + damaged endothelial function
Exclusion
- hepatic and kidney damage,
- IDDM (Insulin Dependent Diabetes Mellitus)
- Freckson V type hyperlipoproteinaemia
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Key Trial Info
Start Date :
February 1 2005
Trial Type :
INTERVENTIONAL
End Date :
August 1 2007
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00350038
Start Date
February 1 2005
End Date
August 1 2007
Last Update
January 23 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sanofi-aventis
Budapest, Hungary